1
|
Affiliation(s)
- Hugo Gerald Schmidt
- Cambridge Centre for Advanced Research and Education in Singapore, 07 RESEARCH Tower, 1 Create Way, Singapore 138602
| |
Collapse
|
2
|
Delineating a green, catalyst free synthesis of a popular nutraceutical methylsulfonylmethane (MSM) in continuous flow. J Flow Chem 2021. [DOI: 10.1007/s41981-021-00186-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
3
|
Guan M, Tian Y, Zhao J, Gu X, Jiang X, Wang X, Zhang Y, Zhang X. Safe Scale-Up of an N-Bromosuccinimide Involved Bromination Reaction. Org Process Res Dev 2021. [DOI: 10.1021/acs.oprd.1c00074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Mingxing Guan
- College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, P. R. China
| | - Yingtao Tian
- Chemical & Analytical Development, Suzhou Novartis Technical Development, Co., Ltd. Changshu, Jiangsu 215537, P. R. China
| | - Jibin Zhao
- Chemical & Analytical Development, Suzhou Novartis Technical Development, Co., Ltd. Changshu, Jiangsu 215537, P. R. China
| | - Xingxian Gu
- Chemical & Analytical Development, Suzhou Novartis Technical Development, Co., Ltd. Changshu, Jiangsu 215537, P. R. China
| | - Xigui Jiang
- Chemical & Analytical Development, Suzhou Novartis Technical Development, Co., Ltd. Changshu, Jiangsu 215537, P. R. China
| | - Xufan Wang
- Chemical & Analytical Development, Suzhou Novartis Technical Development, Co., Ltd. Changshu, Jiangsu 215537, P. R. China
| | - Yongbo Zhang
- Chemical & Analytical Development, Suzhou Novartis Technical Development, Co., Ltd. Changshu, Jiangsu 215537, P. R. China
| | - Xingmin Zhang
- Chemical & Analytical Development, Suzhou Novartis Technical Development, Co., Ltd. Changshu, Jiangsu 215537, P. R. China
| |
Collapse
|
4
|
Allian AD, Shah NP, Ferretti AC, Brown DB, Kolis SP, Sperry JB. Process Safety in the Pharmaceutical Industry—Part I: Thermal and Reaction Hazard Evaluation Processes and Techniques. Org Process Res Dev 2020. [DOI: 10.1021/acs.oprd.0c00226] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- Ayman D. Allian
- Process Development, One Amgen Center Drive, Amgen Inc., Thousand Oaks, California 91320, United States
| | - Nisha P. Shah
- Process Development, Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States
| | - Antonio C. Ferretti
- Chemical Process Development, Bristol Myers Squibb, 556 Morris Avenue, Summit, New Jersey 07901, United States
| | - Derek B. Brown
- Process Development, One Amgen Center Drive, Amgen Inc., Thousand Oaks, California 91320, United States
| | - Stanley P. Kolis
- Small Molecule Design and Development, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Jeffrey B. Sperry
- Vertex Pharmaceuticals, 50 Northern Avenue, Boston, Massachusetts 02210, United States
| |
Collapse
|
5
|
Zhang H, Liu K, Pu Q, Achab A, Ardolino MJ, Cheng M, Deng Y, Doty AC, Ferguson H, Fradera X, Knemeyer I, Kurukulasuriya R, Lam YH, Lesburg CA, Martinot TA, McGowan MA, Miller JR, Otte K, Biju PJ, Sciammetta N, Solban N, Yu W, Zhou H, Wang X, Bennett DJ, Han Y. Discovery of Amino-cyclobutarene-derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors for Cancer Immunotherapy. ACS Med Chem Lett 2019; 10:1530-1536. [PMID: 31749906 DOI: 10.1021/acsmedchemlett.9b00344] [Citation(s) in RCA: 35] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2019] [Accepted: 09/18/2019] [Indexed: 12/18/2022] Open
Abstract
Checkpoint inhibitors have demonstrated unprecedented efficacy and are evolving to become standard of care for certain types of cancers. However, low overall response rates often hamper the broad utility and potential of these breakthrough therapies. Combination therapy strategies are currently under intensive investigation in the clinic, including the combination of PD-1/PD-L1 agents with IDO1 inhibitors. Here, we report the discovery of a class of IDO1 heme-binding inhibitors featuring a unique amino-cyclobutarene motif, which was discovered through SBDD from a known and weakly active inhibitor. Subsequent optimization efforts focused on improving metabolic stability and were greatly accelerated by utilizing a robust SNAr reaction of a facile nitro-furazan intermediate to quickly explore different polar side chains. As a culmination of these efforts, compound 16 was identified and demonstrated a favorable overall profile with superior potency and selectivity. Extensive studies confirmed the chemical stability and drug-like properties of compound 16, rendering it a potential drug candidate.
Collapse
|
6
|
Han C, Alabanza LM, Kelly SM, Orsi DL, Gosselin F, Altman RA. BBDFA: A Practical Reagent for Trifluoromethylation of Allylic and Benzylic Alcohols on Preparative Scale. Org Process Res Dev 2019. [DOI: 10.1021/acs.oprd.9b00201] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Affiliation(s)
- Chong Han
- Department of Small Molecule Process Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Lady Mae Alabanza
- Department of Small Molecule Process Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Sean M. Kelly
- Department of Small Molecule Process Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Douglas L. Orsi
- Department of Medicinal Chemistry, The University of Kansas, Lawrence, Kansas 66045, United States
| | - Francis Gosselin
- Department of Small Molecule Process Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Ryan A. Altman
- Department of Medicinal Chemistry, The University of Kansas, Lawrence, Kansas 66045, United States
| |
Collapse
|
7
|
Bourriquen F, Bruneau-Voisine A, Jeandin A, Stihle E, Fantasia S. Streamlined Synthesis of Diaminopyridines by Pd-Catalyzed Ammonia Coupling with Deactivated Amino-Chloropyridines. Chemistry 2019; 25:9006-9011. [PMID: 31081560 DOI: 10.1002/chem.201902147] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2019] [Indexed: 11/12/2022]
Abstract
An efficient and cost-effective two-step synthesis of diaminopyridines, fundamental building blocks of biologically active compounds, is reported. The advantages over previously reported routes include cost and wider availability of the bromo-chloropyridine starting materials and the straightforward accessibility to an extended array of diaminopyridine regioisomers. The key enabler of this synthetic strategy is the development of an unprecedented palladium-catalyzed coupling reaction of ammonia with chloropyridines deactivated by the presence of an alkylamino substituent. The coupling reaction was accomplished with very low catalyst loadings under remarkably mild reaction conditions, making the system particularly suitable for both academic and industrial applications. The utility of this methodology is exemplified by the application to the synthesis of highly relevant scaffolds, including the synthetic intermediates of the marketed drugs Ribociclib and Palbociclib.
Collapse
Affiliation(s)
- Florian Bourriquen
- Pharmaceutical Division, Small Molecules Technical Development, Process Chemistry and Catalysis, F. Hoffmann-La Roche Ltd, 4070, Basel, Switzerland
| | - Antoine Bruneau-Voisine
- Pharmaceutical Division, Small Molecules Technical Development, Process Chemistry and Catalysis, F. Hoffmann-La Roche Ltd, 4070, Basel, Switzerland
| | - Aliénor Jeandin
- Pharmaceutical Division, Small Molecules Technical Development, Process Chemistry and Catalysis, F. Hoffmann-La Roche Ltd, 4070, Basel, Switzerland
| | - Etienne Stihle
- Pharmaceutical Division, Small Molecules Technical Development, Process Chemistry and Catalysis, F. Hoffmann-La Roche Ltd, 4070, Basel, Switzerland
| | - Serena Fantasia
- Pharmaceutical Division, Small Molecules Technical Development, Process Chemistry and Catalysis, F. Hoffmann-La Roche Ltd, 4070, Basel, Switzerland
| |
Collapse
|
8
|
Martinot TA, Ardolino M, Chen L, Lam YH, Li C, Maddess ML, Muzzio D, Qi J, Saurí J, Song ZJ, Tan L, Vickery T, Yin J, Zhao R. Process Safety Considerations for the Supply of a High-Energy Oxadiazole IDO1-Selective Inhibitor. Org Process Res Dev 2019. [DOI: 10.1021/acs.oprd.9b00105] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Affiliation(s)
- Theodore A. Martinot
- Process Research & Development, MRL, Merck & Co., Inc., Boston, Massachusetts 02115, United States
| | - Michael Ardolino
- Process Research & Development, MRL, Merck & Co., Inc., Boston, Massachusetts 02115, United States
| | - Lu Chen
- WuXi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China
| | - Yu-hong Lam
- Modeling and Informatics, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Chaomin Li
- Process Research & Development, MRL, Merck & Co., Inc., Boston, Massachusetts 02115, United States
| | - Matthew L. Maddess
- Process Research & Development, MRL, Merck & Co., Inc., Boston, Massachusetts 02115, United States
| | - Daniel Muzzio
- Process Research & Development, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Ji Qi
- Process Research & Development, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Josep Saurí
- Process Research & Development, MRL, Merck & Co., Inc., Boston, Massachusetts 02115, United States
| | - Zhiguo J. Song
- Process Research & Development, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Lushi Tan
- Process Research & Development, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Thomas Vickery
- Process Research & Development, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Jingjun Yin
- Process Research & Development, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Ralph Zhao
- Process Research & Development, MRL, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| |
Collapse
|
9
|
Synthesis, in vitro and in vivo evaluation of 18F-fluoronorimatinib as radiotracer for Imatinib-sensitive gastrointestinal stromal tumors. Nucl Med Biol 2017; 57:1-11. [PMID: 29175467 DOI: 10.1016/j.nucmedbio.2017.11.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2017] [Revised: 11/03/2017] [Accepted: 11/15/2017] [Indexed: 01/12/2023]
Abstract
INTRODUCTION Gastrointestinal stromal tumors (GIST) have a wide range of mutations, but can mostly be treated with Imatinib, until eventually resistance towards this tyrosine kinase inhibitor is acquired. Early and non-invasive determination of the sensitivity of the tumor and its metastases towards Imatinib by positron emission tomography (PET) would be beneficial for therapy planning and monitoring. METHODS We developed a synthesis strategy towards the precursor molecule, performed the 18F-synthesis and in the following evaluated the radioligand in vitro regarding its lipophilicity, stability and biological activity (KIT binding properties) as well as its in vivo properties in GIST tumor-bearing mice. RESULTS [18F]fluoronorimatinib could be obtained in an overall radiochemical yield of 22.2±3.3% within 90min. The radioligand showed high GIST cell uptake and was able to distinguish between Imatinib-sensitive and resistant tumor cell lines (GIST-T1, GIST882, GIST430) in vitro. Further biological evaluations of the ligand towards 9 different GIST-relevant KIT mutations showed comparable binding affinities compared to the structural lead Norimatinib (65nM vs. 53nM for wt-KIT). The in vivo evaluation of the newly developed radioligand showed tumor-to-background-ratios comparable to previously described, similar radiotracers. CONCLUSIONS Thus, [18F]fluoronorimatinib is able to distinguish between Imatinib-resistant and sensitive KIT mutations. Although no improvement of in vivo tumor-to-background ratios could be achieved compared to formerly described radioligands, the hepatic uptake could be considerably reduced, being advantageous for the imaging of GIST. Advances in knowledge and implications for patient care: We were able to show that it is possible to significantly reduce the unfavorably high hepatic uptake of small-molecule radioligands applicable for GIST PET imaging. This work can thus be the basis for further work intending to develop a PET-radioligand for Imatinib-dependent GIST imaging.
Collapse
|